HEILONGJIANG, China, Feb. 10 /PRNewswire-Asia/ -- Yanglin Soybean, Inc. (OTC Bulletin Board: YSYB) ("Yanglin" or the "Company"), a leading producer and processor of high-quality, non-genetically modified (non-GM) soybean products in China, today announced that its corporate presentation at the Roth Capital Partners' 21st Annual OC Growth Stock Conference has been moved to Wednesday, February 18th.
This conference will be held from Monday, February 16th through Wednesday, February 18th at The Ritz Carlton, Laguna Niguel. Details of Yanglin's presentation at the conference are as follows:
Date: Wednesday, February 18, 2009
Time: 9:00 - 9:30 P.M. Pacific Standard Time
Yanglin's management team will send three representatives to attend the conference, including Chief Executive Officer, Mr. Shulin Liu, Chief Financial Officer, Mr. Bode Xu, and Director Mr. Yang Miao. The Company's management team will be available to meet with analysts and portfolio managers during this three-day event.
A live webcast of the presentation will be available by accessing the below web site http://www.wsw.com/webcast/roth20/ysyb.ob/ .
About Yanglin
Yanglin Soybean, Inc. is a leading non-genetically modified (non-GM) soybean processor in China. The Company manufactures soybean oil, salad oil and soybean meal with an annual processing capacity of 520,000 metric tons in 2008. During the first nine months of 2008, total revenues reached US$190.2 million. The Company's products are sold directly to its customers or through distributors. Majority of Yanglin Soybean's customers are located in Northern China.
Forward Looking Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release and oral statements made by the Company constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2009 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
